Folgen der COVID-19-Pandemie für Menschen mit Schizophrenie, Demenz und Abhängigkeitserkrankungen

[1]  Baoliang Zhong,et al.  Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study , 2020, Translational Psychiatry.

[2]  S. Papageorgiou,et al.  The impact of COVID‐19 pandemic on people with mild cognitive impairment/dementia and on their caregivers , 2020, International journal of geriatric psychiatry.

[3]  D. Goldsmith,et al.  Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic , 2020, Brain, Behavior, and Immunity.

[4]  G. Koob,et al.  Addiction as a Coping Response: Hyperkatifeia, Deaths of Despair, and COVID-19. , 2020, The American journal of psychiatry.

[5]  S. Trifu,et al.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19 , 2020, Brain sciences.

[6]  A. Ruiz,et al.  Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia , 2020, Frontiers in Aging Neuroscience.

[7]  G. Santangelo,et al.  The Psychological Impact of COVID-19 Pandemic and Lockdown on Caregivers of People With Dementia , 2020, The American Journal of Geriatric Psychiatry.

[8]  A. Venneri,et al.  The Impact of COVID-19 Infection and Enforced Prolonged Social Isolation on Neuropsychiatric Symptoms in Older Adults With and Without Dementia: A Review , 2020, Frontiers in Psychiatry.

[9]  A. Koopmann,et al.  Did the General Population in Germany Drink More Alcohol during the COVID-19 Pandemic Lockdown? , 2020 .

[10]  O. Pogarell,et al.  SARS-CoV-2 Pandemic and Addictive Disorders: Focus on Opioid Dependence and Opioid Maintenance Treatment - The Bavarian Experience , 2020 .

[11]  R. Bernabei,et al.  Neuropsychiatric Symptoms in Elderly With Dementia During COVID-19 Pandemic: Definition, Treatment, and Future Directions , 2020, Frontiers in Psychiatry.

[12]  C. Crunelle,et al.  Self-Reported Alcohol, Tobacco, and Cannabis Use during COVID-19 Lockdown Measures: Results from a Web-Based Survey , 2020, European Addiction Research.

[13]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[14]  A. Mehrotra,et al.  Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine , 2020, Journal of Substance Abuse Treatment.

[15]  A. Mourad,et al.  COVID-19-associated brief psychotic disorder , 2020, BMJ Case Reports.

[16]  A. John,et al.  COVID-19: The Hidden Impact on Mental Health and Drug Addiction , 2020, Frontiers in Psychiatry.

[17]  Yufeng Wei,et al.  Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications , 2020, Pharmaceuticals.

[18]  D. Melzer,et al.  ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank , 2020, medRxiv.

[19]  Vasuki H. Dandu,et al.  Spectrum of neuropsychiatric manifestations in COVID-19 , 2020, Brain, Behavior, and Immunity.

[20]  I. Deary,et al.  Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study based on a community sample , 2020, Brain, Behavior, and Immunity.

[21]  S. Dubey,et al.  COVID-19 and addiction , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[22]  M. Cesari,et al.  Facing Dementia During the COVID‐19 Outbreak , 2020, Journal of the American Geriatrics Society.

[23]  V. Ojetti,et al.  Clinical characteristics and prognostic factors in COVID‐19 patients aged ≥80 years , 2020, Geriatrics & gerontology international.

[24]  M. Cesari,et al.  Providing Simultaneous COVID-19–sensitive and Dementia-Sensitive Care as We Transition from Crisis Care to Ongoing Care , 2020, Journal of the American Medical Directors Association.

[25]  M. Trabucchi,et al.  Clinical Presentation of COVID19 in Dementia Patients , 2020, The journal of nutrition, health & aging.

[26]  R. Armitage,et al.  Substance misuse during COVID-19: protecting people who use drugs , 2020, Public Health.

[27]  F. Pechansky,et al.  The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment. , 2020, Psychiatry research.

[28]  P. Haber,et al.  Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic , 2020, Harm Reduction Journal.

[29]  J. Rehm,et al.  Alcohol use in times of the COVID 19: Implications for monitoring and policy , 2020, Drug and alcohol review.

[30]  B. Pollock,et al.  Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer's Disease and Related Dementias , 2020, The American Journal of Geriatric Psychiatry.

[31]  T. Schulze,et al.  A global needs assessment in times of a global crisis: world psychiatry response to the COVID-19 pandemic , 2020, BJPsych Open.

[32]  W. Honer,et al.  Consensus statement on the use of clozapine during the COVID-19 pandemic , 2020, Journal of psychiatry & neuroscience : JPN.

[33]  N. Volkow.  Collision of the COVID-19 and Addiction Epidemics , 2020, Annals of Internal Medicine.

[34]  José Luis Molinuevo,et al.  Dementia care during COVID-19 , 2020, The Lancet.

[35]  M. Lipsitch,et al.  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[36]  R. Murray,et al.  Schizophrenia and Influenza at the Centenary of the 1918-1919 Spanish Influenza Pandemic: Mechanisms of Psychosis Risk , 2020, Frontiers in Psychiatry.

[37]  G. Onder,et al.  Prevalence and clinical correlates of dementia among COVID‐19‐related deaths in Italy , 2020, Alzheimer's & dementia.

[38]  Ó. Ribeiro,et al.  Dementia and COVID-19: The Ones Not to Be Forgotten , 2020, American journal of Alzheimer's disease and other dementias.

[39]  James G. Scott,et al.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 , 2018, Schizophrenia bulletin.

[40]  Veronica Baud.  Psychopharmakotherapie griffbereit: Medikamente, psychoaktive Genussmittel und Drogen , 2015 .

[41]  D. Piontek,et al.  Inanspruchnahme gesundheitlicher Versorgung durch Alkoholabhängige , 2014, Suchttherapie.

[42]  R. Holle,et al.  A claims data-based comparison of comorbidity in individuals with and without dementia , 2014, BMC Geriatrics.

[43]  E. Severance,et al.  Coronavirus Immunoreactivity in Individuals With a Recent Onset of Psychotic Symptoms , 2009, Schizophrenia bulletin.

[44]  Daniel J Buysse,et al.  The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research , 1989, Psychiatry Research.